BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

WellSpring Pharmaceutical Corporation Emetrol(R) Consumer Brand Achieves Number One Position in Anti-Nausea Category


4/21/2009 9:57:22 AM

SARASOTA, Fla., April 21 /PRNewswire/ -- WellSpring Pharmaceutical Corporation announced earlier today that Emetrol (R), its liquid anti-nausea brand is now the leading product in its category. Based on trailing 52 weeks sales (ending 1/14/09) Emetrol(R) garnered 51.7 % of the brand category displacing all others including private label. The most recent IRI reports indicate that Emetrol (R) sales are up 24% over last year reflecting the fact that it is recommended by name by OB/GYN's, Pediatricians and Pharmacists. Over 90% of OB/GYN's interviewed indicate that they would most likely use Emetrol(R) as first line therapy in treating mild to moderate nausea.

For over 60 years, Emetrol(R) has provided consumers with reliable relief from nausea and vomiting. Emetrol (R) is popular with more and more consumers including women between the ages of 25 and 34 who seek Emetrol(R) due to their doctor or pharmacist's recommendation. Emetrol(R) is specifically recommended because it is safe, effective, and gives fast relief from nausea and vomiting due to upset stomach, flu, and food indiscretions. WellSpring has rolled out a national advertising campaign targeting this population segment. And the National Association of Pediatric Nurse Practitioners (NAPNAP) has selected Emetrol(R) for editorial content in their upcoming issue which reaches 3.5 million women ages 25-48.

WellSpring's President and CEO, Dr. Robert A. Vukovich commented on this announcement: "The Emetrol(R) brand is an important one for our company as we have seen remarkable growth in its sales over this past year. The fact that we are recommended by OB/GYN physicians for their patients experiencing nausea associated with pregnancy and by Pediatricians for children under their care, has proven to be one of the most important attributes of the brand. Containing a unique combination of phosphorylated carbohydrates Emetrol (R) is considered by these physicians as safe and effective for treating mild to moderate nausea. We will continue to invest heavily in the brand with a new national advertising campaign."

WellSpring Pharmaceutical Corporation is a closely held pharmaceutical company marketing both prescription and non-prescription consumer drug brands. The firm has headquarters in Sarasota, Florida and operates a state-of-the-art GMP compliant manufacturing facility in Canada.

Emetrol Website: www.emetrol.com

CONTACT: Wendy Shusko, COO, +1-941-312-4727, Wayne Miller, VP Sales,
+1-941-312-4727, both of WellSpring Pharmaceutical Corporation

Web site: http://www.emetrol.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES